Updates

CSRxP Statement on Nomination of Alex Azar to be Secretary of Health and Human Services

Nov 17, 2017

The Campaign for Sustainable Rx Pricing released the following statement… Read More

Vizient Joins CSRxP as 30th Member of the Coalition

Sep 21, 2017

“We are excited to join CSRxP and be a part of the coalition to achieve reasonable prescription drug prices,” says Jody Hatcher, president, sourcing and collaboration services at Vizient. “Our health care members are facing enormous financial and clinical pressures associated with pharmaceuticals. Read More

37 Signatories Call on Congress to Pass CREATES Act

Sep 20, 2017

37 signatories have called on Congress to pass the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act. This coalition represents a broad-based and diverse cross-section of stakeholders – including providers and payers, physicians and consumers, businesses and unions – all of whom have come together in strong support of this important legislation. Read More

CSRxP Statement on Novartis’ $475,000 Price Tag for Kymriah

Aug 30, 2017

"While we are very excited about the potential for CAR-T therapies to save lives, Novartis’ pricing decision disappointingly pushes an unsustainable trend even closer to the breaking point." Read More

CSRxP Calls for Action on CREATES Act

Jul 27, 2017

CSRxP Calls for Action on CREATES Act The Campaign for Sustainable Rx Pricing… Read More

CSRxP Calls for Further Action on Rx Prices

Jul 12, 2017

CSRxP spokesman Will Holley releases statement following House passage of FDA user fee legislation. Read More

CSRxP Releases Powerful Testimonial: “Debbie’s Story”

Jul 10, 2017

CSRxP Releases Powerful Testimonial: “Debbie’s Story” The… Read More

CSRxP Highlights Big Pharma’s Price Gouging Tactics With New Spot: “The Right”

Jun 19, 2017

“The Right” highlights examples of Big Pharma’s price-gouging tactics, such as Miacalcin’s 3,200% price hike, Daraprim’s 5,000% price hike, and doxycycline’s 9,000% price increase in just six months. These price hikes are part of a longstanding pattern that show no sign of slowing down - in fact, a recent report showed that there were more price hikes in the first quarter of 2017 than there were in the first quarter of 2016. Read More

CSRxP Rolls Out Latest Ad: “Priorities”

May 18, 2017

It's time for Big Pharma to get their priorities straight: American's deserve open and honest prescription drug pricing. Read More

Avik Roy Unveils “The Competition Prescription”

May 16, 2017

Read "The Competition Prescription," a new white paper by Avik Roy, President of Foundation for Research on Equal Opportunity on how federal policy has artificially driven up the cost of prescription drugs, and market-based reforms to bring prices down. Read More

Association for Community Affiliated Plans Joins CSRxP

May 10, 2017

“The people served by ACAP’s members are among the most vulnerable to the out-of-control prices of prescription medications and they have first-hand experience with the effect that Big Pharma’s pricing policies have on real people every day,” said John Rother, Executive Director of CSRxP. Read More

CSRxP Applauds PhRMA’s Newfound Commitment to R&D

May 9, 2017

“If PhRMA’s members are serious about their commitment to affordability, we invite them to join us in supporting common-sense, bipartisan reforms like the CREATES and FAST Generics Acts that address equally-egregious, though less-publicized, anticompetitive abuses as the ones that prompted this change in policy.” Read More